Scientific publications

# Evidence, published and peer-reviewed

More than 120 publications across 15+ years of WEE1 research — covering the mechanism, the biomarker, and the clinical data behind our programs.

Our science → Request a reprint

Featured

## Recently published

Featured · Clinical data

### Phase 2 results: Zent-001 in Cyclin E1-positive platinum-resistant ovarian cancer

Updated safety, efficacy and biomarker findings from our expansion cohort, presented at a major medical oncology congress.

Zentia Clinical Development Team · 2026 Journal of Clinical Oncology (in press)

Peer-reviewed evidence is the foundation of everything we claim — and everything we build next.

Read the announcement →

Selected works

## Selected publications

A representative selection across mechanism, translational science and clinical development.

2026

### Biomarker-defined patient selection in WEE1 inhibitor development: lessons from Cyclin E1 amplification

Kovács R., Osei A., Kim M., et al.

Clinical Cancer Research
2025

### WEE1 inhibition as an oral, non-chemotherapy strategy in platinum-resistant gynecologic cancers

Reeves S., Caputo L., et al.

Gynecologic Oncology
2024

### Mechanistic drivers of WEE1 dependency across tumor types

Kim M., Gupta N., et al.

Cancer Discovery
2023

### Translation of cell-cycle checkpoint biology into targeted therapies

Brooks D., Ward P., et al.

Nature Reviews Cancer
2021

### Cyclin E1 amplification as a predictive biomarker: from hypothesis to companion diagnostic

Osei A., Sandoval R., et al.

The Journal of Molecular Diagnostics
2019

### Selective oral WEE1 kinase inhibition: discovery and preclinical characterization of Zent-001

Kim M., Hoshino Y., et al.

Journal of Medicinal Chemistry

For a full list of publications or to request reprints, contact our medical information team.

Contact medical information →